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Key Points
• In CML, the goals of
treatment are survival
and TFR.
• In this article, we sug-
gest what treatment
policies may be adop-
ted to increase the rate
of TFR.
Several papers authored by international experts have proposed recommendations on the
management of BCR-ABL11 chronic myeloid leukemia (CML). Following these
recommendations, survival of CML patients has become very close to normal. The next,
ambitious, step is to bring as many patients as possible into a condition of treatment-free
remission (TFR). The Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian
Group for Hematologic Diseases of the Adult) CML Working Party (WP) has developed
a project aimed at selecting the treatment policies that may increase the probability of TFR,
taking into account 4 variables: the need for TFR, the tyrosine kinase inhibitors (TKIs), the
characteristics of leukemia, and the patient. A Delphi-like method was used to reach
a consensus among the representatives of 50 centers of the CML WP. A consensus was
reached on the assessment of disease risk (EUTOS Long Term Survival [ELTS] score), on the
deﬁnition of the most appropriate age boundaries for the choice of ﬁrst-line treatment, on
the choice of the TKI for ﬁrst-line treatment, and on the deﬁnition of the responses that do
not require a change of the TKI (BCR-ABL1 #10% at 3 months, #1% at 6 months, #0.1% at
12 months, #0.01% at 24 months), and of the responses that require a change of the TKI,
when the goal is TFR (BCR-ABL1 .10% at 3 and 6 months, .1% at 12 months, and .0.1% at
24 months). These suggestions may help optimize the treatment strategy for TFR.
Submitted 20 August 2019; accepted 4 November 2019. DOI 10.1182/
bloodadvances.2019000865.
Data sharing requests may be e-mailed to the corresponding author, Michele
Baccarani, at michele.baccarani@unibo.it.
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Introduction
Tyrosine kinase inhibitors (TKIs) have been introduced in the
therapy of chronic myeloid leukemia (CML) beginning with imatinib
in 2001.1,2 Four other TKIs have been approved between 2001 and
2013,3-6 and are now available almost worldwide. The first attempt
at establishing an internationally shared policy of treatment with
TKIs was made by a panel of experts under the heading of the
European Leukemia Network (ELN) in 2006,7 revised in 20098 and
2013.9 After 2013, other data have become available. The results of
the IRIS trial, comparing imatinib with interferon-a (IFNa), and of the
trials comparing imatinib with the second-generation TKIs (2GTKIs)
dasatinib and nilotinib, have been updated.10-12 Moreover, the
results of 2 trials comparing imatinib with another 2GTKI (bosutinib),
several retrospective or prospective studies of different TKIs, and
many comprehensive reviews13-33 have been published. The ELN
recommendations have not yet been updated. The National
Comprehensive Cancer Network (NCCN)34 regularly updates
another set of treatment recommendations. The European Society for
Medical Oncology has updated its recommendations in 2017.35 The
definitions of “optimal response” and “failure” (suggesting no
treatment change or a switch to a different TKI, respectively) varied,
but the primary goal of all recommendations thus far was to ensure
the best survival. However, today, the expectation of patients and
doctors has changed, and there is a trend to move the primary goal of
CML treatment from survival to the achievement of a condition of
treatment-free remission (TFR). Therefore, a debate on which
treatment policies should be adopted for achieving TFR is open.
Over the last 20 years, the CML scenario has changed. Initially, due
to the limited availability of TKIs and the rarity of the disease, only
some referral centers could acquire a robust clinical experience.
Today, the management of CML is extended to many centers,
also small centers with limited experience, or even to individual
practitioners. It is uncertain whether treating for TFRmay be allowed
in all centers and to every doctors, or if it is still investigational and
should be limited to referral centers, but the possibility of achieving
TFR can no longer be denied to any patient. The results of several
phase 2 single-arm TFR studies,36-44 individual experience, pa-
tient will, as well as commercial pressure, may bias the choice of
treatment.13,24,26,45-48 For these reasons, the CML Working
Party (WP) of Gruppo Italiano Malattie EMatologiche dell’Adulto
(GIMEMA; Italian Group for Hematologic Diseases of the Adult) has
developed a project that has involved the representatives of
50 hematologic centers, with the purpose of suggesting a treatment
policy aiming to the achievement of TFR.
Material and methods
Fifty Italian centers, responsible for the care of .50% of the Italian
CML patients, appointed a representative who participated actively
in all steps of this project. A questionnaire addressing 326 key
questions was circulated between July and September 2018. All 50
questionnaires were filled in and returned. The responses were
analyzed, and the results were discussed in a first meeting held in
October 2018. A second questionnaire with 70 questions was
elaborated after the first meeting and a second meeting was held on
April 2019. After that, the responses to a third questionnaire with 45
questions were analyzed for conclusions. During the meetings, the
items receiving the consensus of .70% of panel members were
reviewed and finally approved by all members, sometimes with
minor modifications. The items that had not received the consensus
of .70% of panel members were discussed, and the results of the
discussion were included in the second and the third questionnaire.
After the analysis of the third questionnaire, the items that had
reached a consensus of 70% or more were approved by all
members and included in the list of the suggestions. When this
consensus was not reached, it was acknowledged that neither
evidence nor experience were sufficient to make proposals.
The project was not discussed or negotiated with the ELN panel, and,
differently from the ELN recommendations, was specifically and
entirely dedicated to the development of treatment policies finalized
to TFR. M. Baccarani was no longer the coordinator of the ELN panel.
Some senior panel members (M. Baccarani, F. Pane, G.R., G.S., and
S. Soverini) who had been previously members of the ELN panel for
CML recommendations were involved in the discussion, but they did
not fill in the questionnaires. The methodology was quite similar to
the Delphi technique.49 All items were reviewed, discussed, and
approved based on the interpretation of the available data by panel
members and on their practice. The final proposals were not graded.
No statistical procedures were used.
Results
Leukemia: risk
In the era of conventional chemotherapy, almost all patients died of
leukemia. In 1984, a score predicting survival was elaborated by Sokal
et al50; it became familiar worldwide, and was used in the majority of
CML trials, until today because it was also able to predict response and
survival in patients treated with IFNa and TKIs. Later on, 2 additional
scores were proposed, based on patients treated with IFNa (EURO
score)51 and with imatinib (EUTOS score).52 Considering that today
many patients no longer die of leukemia,9,34 a fourth risk score has
been elaborated, to predict the probability of leukemia-related death
(LRD)53 in patients treated with imatinib, the new EUTOS Long Term
Survival (ELTS) score. The ELTS score is based on simple hematologic
data, spleen size, and age, just like the Sokal one. It predicts LRD better
than Sokal, and the main difference is due to the fact that the negative
prognostic weight of age is lower in TKI-treated patients (ELTS) than in
patients treated with conventional chemotherapy (Sokal). Therefore,
Sokal score classifies inappropriately more elderly patients than ELTS
in the intermediate- and high-risk groups, and this is not useful for
planning the intensity of treatment. A comparison of Sokal and ELTS
scores is shown in Table 1. The panel suggests use of the new ELTS
score to assess the baseline CML risk, and suggests that intermediate-
and high-risk patients be grouped together.
Several other risk factors9,34 have been identified, but so far none have
entered into clinical use. An important exception is the presence of
additional clonal chromosome abnormalities in Ph1 cells (additional
clonal chromosome abnormalities [ACA]/Ph1), including so far 18,
1Ph, 119, 121, 117/i17, 11q23, abnormalities of chromosome 3
and 7, and complex karyotypes.56-62 ACA/Ph1 are associated with
poor response to TKIs and higher rate of progression.56-62 They should
be enrolled in specifically designed trials. Presently, we suggest that
they be classified and treated as high-risk patients.
Patient: age
The age distribution of newly diagnosed patients with CML varies,
particularly from western countries, where the median age is close
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to 60 years, to Asia and Africa, where the median age is lower than
50 years.63-65 In Europe,,2% of patients are children or adolescents,
;15% are 18 to 40 years old, ;50% are 41 to 65 years old, ;25%
are 66 to 80 years old, and;6% are.80 years old. Age is an obvious
determinant of life expectancy, is associated with comorbidities, and is
also a prognostic factor of LRD.63-65 However, and more importantly,
it is the need for TFR that depends on age. Obviously, there are
individual variations, but different ages are associated with different
life-styles, different parental and family planning problems, differ-
ent work conditions and career expectations, and different financial
issues. The life of a young person is different from the life of an adult,
of an elderly, and of a very elderly patient. Having settled that every
patient may wish, and has the right, to achieve TFR, the need for TFR
is related to age. Therefore, we suggest identifying 5 age groups:
children and adolescents (,18 years old), young adults (18-40 years
old), adults (41-65 years old), elderly (66-80 years old), and very
elderly (.80 years old). It is important to notice that these age
boundaries have no prognostic value and do not predict the probability
of achieving TFR. Age is important because it is the best objective
variable for the evaluation of the individual need for TFR, helping to
choice the more convenient treatment policy for TFR. Defining age
boundaries rises easy criticisms, but boundaries are always necessary:
we all agree to use boundaries when defining responses, molecular,
cytogenetic, and hematologic, and the risk score.
Patient, health conditions, and comorbidities
General health conditions and several specific comorbidities,
irrespective of the relationship with age, are important variables
that may influence the treatment plan, particularly in the first-line.66
For each TKI, the respective prescribing information alert that some
comorbidities may represent a problem requiring careful monitoring,
but do not mention specific contraindications. Many comorbidities
have been already identified.67 The panel was asked to specify
which comorbidities can represent an obstacle to the use of any
particular TKI in first-line. A panel consensus was reached for
nilotinib, dasatinib, and ponatinib. Strong contraindications to nilotinib
and ponatinib include a history or a condition of ischemic heart
disease, ranging from myocardial infarction to angina (symptom-
atic, or under medical treatment, or having required a coronary
bypass or stents), of peripheral arterial thrombosis, of cerebro-
vascular events, and of diabetes mellitus. Strong contraindications
to dasatinib include a history or a condition of a pleuropulmonary
disease, including pulmonary fibrosis, respiratory failure, and pulmo-
nary arterial hypertension. No strong contraindications were sug-
gested for imatinib and bosutinib. If a change of the TKI is planned, in
a second or a subsequent line, for resistance to the previous TKI,
these comorbidities have only the value of an alert because the risk of
leukemia progression may overcome the risk of complications.
TKIs: efficacy
Four TKIs, imatinib, dasatinib, nilotinib, and bosutinib, have been
approved and are available in first-line, without limitations, although
the criteria for the reimbursability of these TKIs differ from country
to country. The approval of 2 GTKIs was based on the 1-year results
of company-sponsored registration trials3,4,6 (Table 2). A 5-year
update of these trials is available only for dasatinib and nilotinib.11,12
The results can be summarized as follows: the patients treated with
any of the 3 2GTKIs achieved faster and deeper molecular responses,
as compared with those treated with imatinib. Progression-free
survival (PFS) and overall survival (OS) at 5 years, and the rate of
patients switching from the first-line TKI to another TKI, were
almost the same with imatinib, dasatinib, and nilotinib. Such data
are not yet available for bosutinib. Median age was 46 to 49 years
in the DASISION4 and ENESTnd3 trials, and 52 to 53 years in the
Table 1. A summary of themain data comparing the application of the Sokal risk score and of the new ELTS risk score to newly diagnosed CML
patients
Reference* No. of patients TKI Risk distribution, OS, and LRD
Low risk Intermediate risk High risk
SOKAL ELTS SOKAL ELTS SOKAL ELTS
Pfirrmann et al53 5154 Imatinib
% of patients 38 56 38 29 23 14
10-y OS, % 89 88 81 79 75 68
6-y LRD, % 3 2 4 5 8 12
Castagnetti et al54 904 Imatinib/ 2GTKI
% of patients 40 57 39 30 21 13
8-y OS, % 95 94 85 81 84 61
8-y LRD 2 2 6 9 10 14
Geelen et al55
709 Imatinib
% of patients 25 47 43 36 32 17
8-y OS, % NR 89 NR 67 NR 55
8-y LRD, % NR 1 NR 8 NR 5
244 2GTKI
% of patients 27 49 41 35 32 16
8-y OS, % NR 92 NR 78 NR 77
8-y LRD, % NR 0 NR 0 NR 6
Sokal risk score50; the new ELTS risk score.53 In all 3 studies, the ELTS score identified similar proportions of patients: 55%, 57%, 47%, and 49%, low; 28%, 30%, 36%, and 35%,
intermediate; 13%, 13%, 17%, and 16%, high. In all 3 studies, the proportion of high-risk patients was higher with Sokal than with ELTS. This is due to the fact that age weighs more on
Sokal than on ELTS calculation because, in the era of conventional chemotherapy, the prognostic value of age was higher than it is today in the TKI era. ELTS high-risk patients have an
inferior OS and a superior LRD rate, as compared with Sokal high-risk ones. The calculation of the ELTS risk score is as follows: 0.0025 3 (age/10)3 1 0.0615 3 spleen 1 0.1052 blasts
1 0.4104 3 (platelet count/1000)20.5, where age is in years, spleen in centimeters, maximum distance below costal margin, manual palpation, blasts are the percentage of blasts in blood.53
Risk score: low, #1.5680; intermediate, 1.5680 2 #2.2185; high, .2.2185.
LRD, leukemia-related death; NR, not reported; OS, overall survival.
*Pfirrmann et al53 (5154 patients treated with imatinib); Castagnetti et al54 (559 patients treated with imatinib, 345 pts treated with 2GTKIs, with no reported difference between imatinib
and 2GTKIs), ASH 2018 (GIMEMA data); Geelen et al55 (709 patients treated with imatinib and 244 patients treated with 2GTKIs) (Dutch and Swedish registries data).
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BFORE trial,6 far less than the median age of unselected newly
diagnosed patients. This point is important because these results
may be erroneously interpreted as a general superiority of 2GTKIs,
whereas superiority was found in an age-selected population of
young and adult patients, so that the difference cannot be extended
as such to all patients. A fifth TKI, ponatinib, has been approved
(PACE study)5 only in second-line (in some countries after failure
of 2GTKIs, in some countries also after imatinib failure), or in
patients with the T315I mutation. There are no studies comparing
a 2GTKI with another 2GTKI, either in first-line or in second-line.
TKIs, toxicity, and tolerability
Toxicity and tolerability have been the object of a recent, comprehen-
sive, critical review.67 It is relevant to consider that all the comparative
trials were designed, sponsored, performed, and analyzed by
companies that had an obvious interest in the development of
2GTKIs. Moreover, in all registration studies, the criteria for patient
selection, particularly age and comorbidities, and the rigid criteria
of treatment adaptation, limit the applicability of the results to
“real-life” patients. Toxicity and tolerability were compared only
between imatinib and 2GTKIs because there are no studies
comparing the 2GTKIs. Based on the interpretation of the
available data and on the experience matured with practice, the
panel has concluded that nilotinib and ponatinib may expose
the patient to metabolic and cardiovascular toxicity, and dasatinib
to pleuropulmonary toxicity, whereas the toxicity of imatinib and
bosutinib is generally weak, although it may affect considerably the
quality of life. Concerning tolerability, the side effects are different
according to the TKI, but no major differences were identified, and
no consensus was reached.
TKIs: dose
All TKIs were approved and registered at a fixed dose. A change of
the dose is allowed only in case of toxicity or tolerability. Some studies
have stressed the importance of taking always the full registered dose
and have highlighted the problem of compliance.68,69 Compliance is
important and all patients should take the standard dose, whenever
tolerated. However, it has not been confirmed that a full dose is
necessary in all patients, when the dose is adapted to tolerance.70-72
Because the relationship between the dose and the response
can easily be monitored, the panel agreed that greater flexibility
should be allowed for the use of TKIs at a reduced dose,73 so
that in a patient who cannot tolerate the standard full dose, but
has achieved an optimal response, the TKI dose should not be
increased.
TKIs: cost
The costs of the TKIs are very different, but are always a heavy
financial burden with the exception of the generic formulations of
imatinib.74-76 In Italy, the yearly cost ranges from a few hundreds
euro for generic imatinib, to ;10000 euro for branded imatinib
(Glivec), ;35000 euro for nilotinib (Tasigna), ;45000 euro for
dasatinib (Sprycel) and bosutinib (Bosulif), and ;75000 euro for
ponatinib (Iclusig). Generic, cheaper formulations of nilotinib and
dasatinib will soon be available.
Response assessment: monitoring
The response is evaluated by cytogenetic and/or molecular tests.77
Cytogenetic monitoring requires at least 2 or 3 marrow biopsies,
starting from the third month until the achievement of a complete
Table 2. The main 1-year results of the company-sponsored trials that were considered for approval of 2GTKIs in the first-line setting by the
FDA and the EMA
ENESTnd DASISION BFORE
Imatinib Nilotinib Imatinib Dasatinib Imatinib Bosutinib
Daily dose, mg 400 3 1 300 3 2 400 3 1 100 3 1 400 3 1 400 3 1
No. of patients 282 283 259 260 246 246
Median age, y 46 47 49 46 53 52
Low risk, % 37* 37* 33† 33† 39* 38*
Intermediate risk, % 36* 36* 48† 47† 39* 31*
High risk, % 28* 28* 19† 19† 21* 21*
CCyR, by 1 y 69%; P , .001 80% 72%; P , .001 83% 66%; P , .007 77%
MMR, at/by 1 y at 22%; P , .001 44% by 28%; P , .001 46% at 37%; P 5 .02 47%
D/C, in 5 y 50% 40% 37% 39%
MMR, by 5 y 60%; P , .0001 77% 66%; P 5 0.0002 76%
MR 4.0, by 5 y 42%; P , .0001 66% NR
MR 4.5, by 5 y 31%; P , .0001 54% 33%; P 5 .02 42%
PFS, 5-y 91% 92% 85% 86%
OS, 5-y 92% 94% 90% 91%
LRD, 5-y 6%; P 5 .02 2% NR
For ENESTnd11 and DASISION,12 also the follow-up results, at 5 years, are shown, confirming a higher rate and depth of molecular response, but showing no superiority in PFS and OS.
From the ENESTnd study, a small but significant difference in leukemia-related deaths was also reported.
at, the proportion of patients with that response at 1 year; by, cumulative incidence of that response after 1 year or 5 years; CCyR, complete cytogenetic response (Ph1 0); D/C,
discontinued for ever the treatment assigned; EMA, European Medicine Agency; FDA, Federal Drug Administration; MMR, major molecular response (BCR-ABL1 #0.1%IS); MR 4.0, BCR-
ABL1 #0.01%IS; MR 4.5, BCR-ABL1 #0.0032%IS; PFS, progression-free survival.
*Sokal risk.
†EURO risk.
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cytogenetic response (CCyR), to obtain the cells for chromo-
some banding analysis (CBA) of at least 20 marrow cell
metaphases.77 The panel acknowledged the historic importance
of cytogenetic monitoring, but reached a full consensus that
cytogenetics alone is no longer sufficient for disease monitoring.
However, cytogenetics is always mandatory at baseline, as well
as in case of treatment failure and in some selected cases, like
in cases with ACA/Ph1 at baseline, and cases with atypical
transcripts that cannot be quantified. Instead, molecular moni-
toring requires only a blood sample. It is based on a standardized
assay, real-time quantitative polymerase chain reaction (qPCR),
which has been internationally recognized, used and validated
for .10 years.78-81 A qPCR should be performed at least every
3 months. Longer intervals would compromise the control of
leukemia in the patients who have not achieved a major molec-
ular response (MMR), and would not be sufficient to assess the
stability of deep molecular response (DMR) in the patients who
may become eligible for TFR.
Response to first-line treatment
The 2013 ELN recommendations9 proposed defining the response
as optimal and failure. In the NCCN guidelines,34 the ELN definition
of optimal corresponds to the recommendation to continue the
same TKI, whereas the ELN definition of failure corresponds to the
suggestion to change the TKI. There are data showing that failure
on imatinib can be successfully rescued with 2GTKIs, whereas
there are less data in cases of failure on 2GTKIs. However, also
in this case, the switch to another 2GTKI is necessary. The ELN
suggested a third type of response,” warning,” formerly “sub-
optimal,” as an alert suggesting a closer monitoring of the response.
This definition may be useful for the early response, but not for later
responses. We propose substituting “warning” with “nonoptimal,”
Table 3. The definition of response to first-line treatment, as proposed by the panel, when TFR is the primary goal
Optimal Nonoptimal Failure/resistance
Continue the same TKI Switching to another TKI is optional Changing the TKI is mandatory
3 mo CHR, and BCR-ABL1 #10, or BCR-ABL1 .10, not confirmed NA No CHR, or BCR-ABL1 .10, confirmed
6 mo BCR-ABL1 #1 BCR-ABL .1-10 BCR-ABL1 .10
12 mo BCR-ABL1 #0.1 BCR-ABL1 .0.1-1 BCR-ABL1 .1
24 mo BCR-ABL1 #0.01 BCR-ABL1 .0.01-0.1 BCR-ABL1 .0.1 or an increase of BCR-ABL1 of at least 1 log
or a mutation
If the BCR-ABL1 level at 3 months is .10%, the qPCR must be repeated immediately. If it decreases to ,10%, the response becomes optimal; if it remains .10%, the response
becomes a failure. Notice that a more precise definition of the molecular response at 3 months is not only beneficial for the patients, but is also cost-effective because the cost of an extra
qPCR is fully covered by the differences in cost between imatinib and 2GTKIs.
CHR, complete hematological response; NA, not applicable.
Table 4. A comparison of the classification of the response in the first-line setting, with the ELN 2013 and the NCCN 1.2019 classifications
Optimal Warning or nonoptimal Failure
ELN 2013 GIMEMA 2019
NCCN
1.2019 ELN 2013
GIMEMA
2019
NCCN
1.2019 ELN 2013 GIMEMA 2019
NCCN
1.2019
Baseline NA NA NA High risk, or
CCA/Ph1,
major route
NA NA NA NA NA
3 mo BCR-ABL1
#10% or
Ph1 #35%
BCR-ABL1 #10% or
BCR-ABL1 .10%,
not confirmed
BCR-
ABL1
,10%
BCR-ABL1
.10%, or Ph1
35%-95%
NA BCR-ABL1
.10%
No CHR, or Ph1 .95% No CHR, or BCR-ABL1
.10% confirmed
NA
6 mo BCR-ABL
#1% or Ph1
0
BCR-ABL1 #1% BCR-
ABL1
,10%
BCR-ABL1 1%-
10% or Ph1
1%-35%
BCR-ABL1
.1%-10%
NA BCR-ABL1 .10% or
Ph1 .35%
BCR-ABL1 .10% BCR-
ABL1
.10%
12 mo BCR-ABL1
#0.1%
BCR-ABL1 #0.1% BCR-
ABL1
#1%
BCR-ABL1
0.1%-1%
BCR-ABL1
.0.1%-1%
BCR-ABL1
.1%-
10%
BCR-ABL1 .1% or Ph1
.0
BCR-ABL1 .1% BCR-
ABL1
.10%
Then* BCR-ABL1
#0.1%
BCR-ABL1 #0.01% BCR-
ABL1
#1%
CCA/Ph2 (27,
7q2)
BCR-ABL1
.0.01%-
0.1%
NA Loss of CHR, or CCyR, or
MMR, or mutations, or
CCA/Ph1
BCR-ABL1 .0.1% or
mutations, or BCR-ABL1
increase of .1 log
BCR-
ABL1
.1%
ELN 2013 and the NCCN 1.2019 classifications.9,34 Notice that for the GIMEMA classification it is mandatory to repeat immediately the qPCR if at 3 months the BCR-ABL1 level is
.10%. If the BCR-ABL1 level drops to #10%, the response turns to optimal. If it is confirmed to be .10%, the response turns to failure/resistance. Therefore, the GIMEMA classification
does not foresee a “nonoptimal” response at 3 months. The cost of an extra qPCR not only allows the patient to make the best choice, but is also fully covered by the cost differences
between imatinib and 2GTKIs. At baseline, high-risk and clonal chromosome abnormalities (CCA)/Ph1 are no longer classified as “warning” because they are included in the high-risk
treatment group. The ELN term “warning” is substituted by the term “nonoptimal.” This is not a trivial difference because the meaning of “warning” was “be careful and monitor the response
more frequently,” whereas “nonoptimal” means that it opens an option for a switch, depending not only on the response but also on the patients (age, health conditions, comorbidities, quality
of life, etc). At 6 and 12 months, the GIMEMA and ELN 2013 classifications are identical. After 12 months, the GIMEMA panel has agreed on more stringent definitions of optimal response,
from BCR-ABL1 #0.1% to BCR-ABL1 #0.01% for optimal response, and from BCR-ABL .1% to BCR-ABL1 .0.1% for failure. The 1.2019 NCCN criteria are much less stringent
because after 1 year (at 15 months) only a BCR-ABL1 level .1% mandates a change of treatment. Notice that GIMEMA definitions refer to TFR, whereas ELN and NCCN definitions refer
to survival.
*At any time for ELN 2013, at 24 months for GIMEMA, at 15 months for NCCN 1.2019.
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where “nonoptimal” is not an alert, but opens an option for a switch,
the decision of switching depending on the characteristics of the
patients (age, health conditions, comorbidities, quality of life, etc).
The proposed classification of the response to first-line treatment
is shown in Table 3. A comparison of this classification with the
ELN 2013 and the NCCN 1.2019 classifications is shown and
commented on in Table 4.
Response to second-line and subsequent lines
of treatment
The definition of the response to second- and subsequent lines of
treatment is useful because up to 50% of newly diagnosed patients
may change the first TKI, sooner or later, for several reasons. Because
TFR may similarly be the main goal of second-line treatment, the panel
agreed to suggest that the response to second-line should be
monitored and classified like the response to first-line (Table 5).
In third and fourth line, and in case of a late switching in search
of a deeper molecular response, the panel agreed that neither
evidence nor experience were sufficient to make specific recom-
mendations, so that a personalized evaluation of any single patient is
more appropriate.
The choice of the TKI: first-line setting
The choice of the first-line TKI has not yet been settled, and is a
matter of debate.9,34,82,83 Panel members were required to indicate
which TKI they are currently prescribing in the first-line setting. The
responses are shown in Figure 1, as a percentage of the answers
of panel members. Because several members indicated .1 TKI,
the total of the responses may exceed 100%. A consensus was
reached for the choice of a 2GTKIs, in all young patients (18-
40 years) and in intermediate- and high-risk adult patients (41-
65 years), and for the choice of imatinib, in low-risk elderly patients
(66-80 years) and in all very elderly patients (.80 years).
However, in low-risk adults (41-65 years) and in intermediate-
and high-risk elderly patients (66-80 years), a consensus was not
reached. It should be noticed that the 2013 ELN recommendations
did not assign a priority to any TKI. The 1.2019 NCCN guidelines did
not assign a priority for low-risk patients, irrespective of age, but
suggested some priority to 2GTKIs, including bosutinib, in high- and
intermediate-risk ones, not elderly.
The choice of the TKI: after first-line
All TKIs were approved for second-line treatment based on company-
sponsored, phase 2, single-arm trials.84 No academic, investigator-
initiated studies have addressed a comparison among the available
TKIs. Therefore, the data are not sufficient to make suggestions
regarding the choice of the TKI in the second- or subsequent-line
setting, apart from the differential sensitivity in patients with the
presence of BCR-ABL1 point mutations (Table 6). Because the
Table 5. A simplified evaluation of the response to treatment in the
second and subsequent lines of treatment
Response to
Second-line TKI
In case of failure, toxicity, or intolerance Same as response to first-
line
In case of early switch (6 and 12 mo) for nonoptimal
response
Same as response to first-
line
In case of late switch for nonoptimal response Personalized evaluation
Third- or fourth-line TKI Personalized evaluation
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Figure 1. Choice of TKIs in the first-line setting. (A) Percentage of low-risk patients. (B) Percentage of intermediate- plus high-risk patients. The indications of 50 panel
members for the choice of the TKI in the first-line setting, according to age and to ELTS risk, in the absence of strong contraindications to dasatinib or nilotinib, are shown. The
numbers over the bars express the proportion of panel members who have assigned priority to each TKI, respectively. With 1 exception (.80 years, low risk), the total of the
numbers over the columns is higher than 100% because several panel members indicated .1 TKI. Some panel members also included bosutinib, although data and experi-
ence with bosutinib are still limited. A consensus for 2GTKIs (dasatinib or nilotinib) was reached in all young patients (18-40 years old) and in intermediate- plus high-risk adult
patients (41-65 years old). A consensus for imatinib was reached in low-risk elderly patients (66-80 years old) and in all very elderly patients (.80 years old). No consensus
was reached in intermediate- plus high-risk adult (41-65 years old) and elderly patients (66-80 years old). Low-risk patients account for ;10%, 30%, 15%, and 4% in each age
group, whereas intermediate- and high-risk patients account for ;6%, 20%, 10%, and 3%, respectively, in each age group. Notice that the 2013 ELN recommendations did
not assign any priority to any TKI. Also, the 1.2019 NCCN guidelines did not assign any priority as far as low-risk patients are concerned, irrespective of age, but suggested
some priority for 2GTKIs, including bosutinib, in high- and intermediate-risk ones, not elderly.
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detection of a mutation is the only factor that can specifically guide the
choice of another TKI,85 when a switch is planned for resistance/failure,
a mutational analysis should always be performed using at least Sanger
sequencing (SS), and whenever possible using next-generation
sequencing (NGS), which is not yet widely available, but being
more sensitive than SS86-90 can avoid a wrong choice in up to 25% of
cases. Whether mutational analysis should be performed in the case
of nonoptimal response has been debated, but a consensus was not
reached. Apart from mutations, the characteristics of the patient (age
and comorbidities) and the toxicity profile of the TKIs count.
The switch from first-line
In the case of failure/resistance, at any time point, including 3 months,
the change of the TKI is appropriate, also if the first-line TKI was
a 2GTKI. In the case of nonoptimal response, the change from a TKI
to another TKI is optional, if it is believed that it may help to achieve
a deeper molecular response and to bring the patient to TFR. There
are some data,20,26,32,43 and there is some experience, of switching
from imatinib to a 2GTKI, not from a 2GTKI to another TKI. All
studies suggest that such a switch may increase the rate of deep
molecular response (DMR), hence the number of patients eligible
for treatment discontinuation and TFR, but, regrettably, all of these
studies are single-arm and do not allow for calculation of the benefit
of a switching policy against the risk of increased toxicity. The panel
did not reach a consensus, either pro or con.
Treatment discontinuation and TFR
Many studies, some retrospective and some prospective, have shown
beyond any doubt that a consistent proportion, ranging between
30% and 70%, of the patients who discontinue treatment after
having achieved a DMR (MR 4.0, BCR-ABL1 #0.01%IS, or MR 4.5,
BCR-ABL1 #0.0032%IS) may remain treatment-free for an as-yet
undefined period of time.36-48 It is important to underline that the
patients with molecular relapse after discontinuation do not progress,
and are almost all able to achieve DMR again upon retreatment, and
that some of them can become eligible for a second attempt of
treatment discontinuation. The probability of achieving TFR may
depend on several factors: leukemia or patient characteristics, TKI
type, treatment duration, DMR duration, etc.36-48 Based on the
interpretation of the available data and on their experience,
the panel members agreed that neither age nor risk are relevant.
To ensure safety and avoid disease progression, the minimum
duration of treatment should be 3 years with a 2GTKI and 5 years
with imatinib. The minimum duration of a stable DMR should be
2 years, with any TKI. There was no consensus on the “optimal”
duration of treatment and of DMR, as well as on the depth of
the molecular response, MR 4.0 or MR 4.5. After discontinua-
tion, patients must be monitored monthly by qPCR for at least
6 months,26,37-44,47 but there was no consensus on the frequency
of monitoring after the first 6 months, either monthly, or bimonthly,
or every 3 months.
Pregnancy: conception
Safe parenting, an important goal of a treatment policy aiming at
TFR, has been the subject of recent reviews.91,92 The panel agreed
that TKIs should not be used during pregnancy due to their potential
teratogenicity, and must be discontinued as soon as the pregnancy
starts. Pregnancy can also be planned in the case of MMR, provided
that the MMR has been stable for a minimum of 2 years, and that
treatment has been stopped. For male patients, the panel agreed
that imatinib, dasatinib, and nilotinib should not be stopped.
However, male patients should be advised that data on bosutinib
and ponatinib are not yet sufficient.
Discussion
The first pivotal report on TFR was published in 2007.36 Since then,
the interest in TFR has increasingly grown. However, regrettably, no
trials were performed to compare the efficacy of different treatment
policies and different TKIs for TFR, with the exception of an ongoing
GIMEMA trial (SUSTRENIM), investigating the 5-year TFR rate in
newly diagnosed CML patients treated first-line with nilotinib or with
imatinib followed by switch to nilotinib in the case of nonoptimal
response.93 SUSTRENIM results will be available not earlier than
Table 6. List of the 35 most frequent BCR-ABL1 kinase domain
mutations associated with resistance to TKIs (based on the
integration of in vitro IC50 data and in vivo observations)
Mutation TKI(s) to which the mutation confers resistance
M244V Imatinib
L248V Imatinib
G250E Imatinib
Q252H Imatinib
Y253H Imatinib, nilotinib
E255V Imatinib, nilotinib, bosutinib
E255K Imatinib, nilotinib, bosutinib
L273M Imatinib
D276G Imatinib
T277A Imatinib
E279K Imatinib
V299L Dasatinib, bosutinib
F311L Imatinib
T315I Imatinib, nilotinib, dasatinib, bosutinib
T315A Dasatinib
T315M Ponatinib
T315L Ponatinib
F317L Imatinib, dasatinib
F317V Imatinib, dasatinib
F317I Imatinib, dasatinib
F317C Imatinib, dasatinib
M351T Imatinib
E355G Imatinib
F359C Imatinib, nilotinib
F359I Imatinib, nilotinib
F359V Imatinib, nilotinib
E379K Imatinib
L384M Imatinib
L387M Imatinib
L387F Imatinib
H396R Imatinib
H396P Imatinib
E459K Imatinib
F486S Imatinib
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3 years from now, so the debate is still open. Strong pressure exists
toward privileging TFR over privileging survival, resulting in a kind of
equilibrium that on one hand may be wise, but on the other hand is
ambiguous, implying subjective decisions. The GIMEMA CML WP
has privileged TFR over survival, as the main goal, for virtually all
patients, and has undertaken a project ending with specific treatment
suggestions for safe achievement of TFR, preserving patients from
exposure to unnecessary potentially more toxic drugs, but maximizing
the probabilities of achieving TFR.
Age boundaries have been proposed not for the prognostic value of
age, but considering age as a measure of the need of achieving
TFR. Strong comorbidities were identified because they are a factor
as important as the potency of the TKI, for the choice of the TKI in
the first-line setting. For the first time, a specific suggestion has
been made on the choice of the first-line TKI. The definitions of the
response to first-line treatment, especially at 3 and 24 months, were
made more stringent, and were also adopted for the definition of the
response to second-line treatment. It is not yet clear whether the
same definitions should also be adopted when the primary goal is
survival, in patients where TFR cannot be achieved. Sometimes, the
data are still incomplete or missing, and the opinions are different,
so that it has been acknowledged that sometimes neither evidence
nor experience were sufficient to make a suggestion. The debate on
the cost-to-benefit ratio of using 2GTKIs is still open, and is hot.76,94
Our suggestions are not guidelines, and have no professional or
legal implications, but may help optimize the treatment of CML for
TFR, not only increasing the TFR rate but also limiting toxicity and
controlling the cost.
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